Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 1, p. S12, 2020. Disponível em: https://skin.dermsquared.com/skin/article/view/826. Acesso em: 19 apr. 2025.